One-year results for STELARA in Crohn’s disease – The head-to-head SEAVUE Study

Returning guest, Dr. Andrew Greenspan, Vice President of Immunology Medical Affairs at Janssen discusses recent data from the Phase 3b SEAVUE study, the first head-to-head study of biologic therapies in patients with Crohn’s disease, evaluating the safety and efficacy of STELARA® (ustekinumab) compared with adalimumab through one year of treatment in biologic-naïve patients. These data were presented at this year’s Digestive Disease Week (DDW) Virtual 2021, where Janssen Immunology presented 20 abstracts in total from the company’s gastroenterology portfolio and pipeline.

As Vice President of Immunology Medical Affairs, Andrew Greenspan, M.D., is responsible for leadership and oversight of Immunology Medical Affairs activities supporting REMICADE® (infliximab), SIMPONI® (golimumab), SIMPONI ARIA® (golimumab for infusion), STELARA® (ustekinumab) and TREMFYA® (guselkumab) for a wide range of diseases, including rheumatoid arthritis, Crohn’s disease, ulcerative colitis and psoriasis.

Listen on Soundcloud.

Liked it? Take a second to support healthprofessionalradio on Patreon!


Leave a Reply

You must be logged in to post a comment.